Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for HIND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 33.33%
March 31, 2026 44.30%
December 31, 2025 53.01%
September 30, 2025 43.93%
June 30, 2025 42.60%
March 31, 2025 75.98%
December 31, 2024
September 30, 2024 38.70%
June 30, 2024 57.71%
March 31, 2024 59.93%
December 31, 2023 92.94%
September 30, 2023 59.77%
June 30, 2023 52.97%
March 31, 2023 53.52%
December 31, 2022 51.45%
September 30, 2022 75.09%
June 30, 2022 65.11%
March 31, 2022 49.92%
December 31, 2021 56.52%
September 30, 2021 57.58%
Date Value
June 30, 2021 61.01%
March 31, 2021 70.91%
December 31, 2020 51.17%
September 30, 2020 63.33%
June 30, 2020 49.18%
March 31, 2020 30.64%
December 31, 2019 20.33%
September 30, 2019 -23.72%
June 30, 2019 -62.18%
March 31, 2019 30.59%
December 31, 2018 26.13%
September 30, 2018 52.53%
June 30, 2018 36.60%
March 31, 2018 42.87%
December 31, 2017 53.90%
September 30, 2017 52.85%
June 30, 2017 49.57%
March 31, 2017 44.09%
December 31, 2016 -12.82%
September 30, 2016 16.69%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Cardiac Biotech Solutions, Inc. 0.00%
Anika Therapeutics, Inc. 65.15%
Enovis Corp. 54.51%
Edwards Lifesciences Corp. 78.09%
Perspective Therapeutics, Inc. -1.31K%

Gross Profit Margin (Quarterly) Related Metrics